Eloralintide (LY3841136)
Eloralintide, also known as LY3841136, is an investigational, long-acting amylin receptor agonist developed by Eli Lilly for weight-management research. It is not a GLP-1, GIP or glucagon agonist; it belongs to a distinct pharmacological class centered on the amylin pathway and satiety signaling.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
This page is a research monograph. It is not a use protocol, medical advice or administration guidance.
How it works
Amylin is a peptide hormone involved in satiety, food-intake regulation, gastric emptying and postprandial metabolic context. Eloralintide is designed as a selective amylin receptor agonist with emphasis on AMY1R. This distinguishes it from molecules based on GLP-1, GIP or glucagon agonism.
- Translational literature examines AMY1R selectivity, food-intake reduction and body-composition changes in preclinical models.
- Clinical development focuses on weight, tolerability, pharmacokinetics and gastrointestinal safety markers.
Quick Research Summary
Eloralintide / LY3841136 is presented here as a research monograph for scientific reading. This page summarizes mechanism, clinical-study arms, efficacy signals, safety and limitations without converting the data into use guidance.
- Class: Selective amylin receptor agonist with research emphasis on the AMY1R pathway.
- Mechanistic distinction: It is not a GLP-1, GIP or glucagon agonist.
- Phase 1: Single ascending dose data are available for safety, tolerability, pharmacokinetics and early weight signal.
- Phase 2: 48-week data in adults with obesity or overweight without type 2 diabetes.
- Status: Investigational compound, without FDA or EMA approval.
Studied Clinical Dose Arms
| Phase | Design/context | Studied arms | Population | Key context |
|---|---|---|---|---|
| Phase 1 | Single ascending dose | 0.04 mg to 12 mg | Healthy participants | Safety, tolerability, pharmacokinetics and early weight signal. |
| Phase 1 | Early exploratory signal | 4 mg and 12 mg | Healthy participants | At week 4, approximately -2.5% and -4.4% weight change was reported versus approximately +0.6% with placebo. This is not a final efficacy conclusion. |
| Phase 2 | 48 weeks, placebo comparator | 1 mg, 3 mg, 6 mg, 9 mg, 6/9 mg escalation, 3/6/9 mg escalation | Adults with obesity or overweight without type 2 diabetes | Mean weight change: -9.5%, -12.4%, -17.6%, -20.1%, -19.9%, -16.4%, respectively; placebo -0.4%. |
Phase 2 endpoints were reported using the efficacy estimand and were not adjusted for multiplicity according to Lilly’s release.
Research overview
Eloralintide, also known as LY3841136, is an investigational, long-acting amylin receptor agonist developed by Eli Lilly for weight-management research. It is not a GLP-1, GIP or glucagon agonist; it belongs to a distinct pharmacological class centered on the amylin pathway and satiety signaling.
- Research area: obesity and weight-management research in clinical-study context.
- Available evidence: translational research, Phase 1 and Phase 2 release/publication.
- Reading boundary: this monograph does not provide a use protocol or administration recommendation.
Clinical development timeline
Cell and animal studies examined selectivity, food intake, body weight and tolerability versus non-selective amylin analogs.
Preclinical background, not proof of clinical outcome.
Single-dose arms from 0.04 mg to 12 mg were studied for safety, tolerability, pharmacokinetics and early weight signal.
Early exploratory signal.
A 12-week study with once-weekly subcutaneous dosing without escalation, across 5 cohorts. Mean body-weight change at week 12 ranged from -2.6% to -11.3% across cohorts, with minimal gastrointestinal adverse events.
Published Phase 1 (Diabetes Obes Metab 2026); an early but controlled signal.
A 48-week study with placebo comparator and multiple Eloralintide arms.
Sponsor-reported release and publication, with endpoints not adjusted for multiplicity.
Lilly announced plans to initiate Phase 3 studies as monotherapy for obesity and evaluation as a complementary option with incretin therapy.
No completed Phase 3 outcomes are presented in this monograph.
Registered studies evaluate eloralintide in combination: with macupatide (Phase 2/2b, NCT07589608 and NCT07215559) and with tirzepatide (Phase 2 NCT06603571, preceded by Phase 1 studies). The question is whether distinct metabolic axes can be combined.
No published results; not a combination recommendation.
Efficacy Signals
Lilly’s release describes a 48-week Phase 2 signal in 263 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes. Reported mean body-weight reductions ranged from 9.5% to 20.1% versus 0.4% with placebo. These data are not a head-to-head comparison with GLP-1, GIP, glucagon or other amylin molecules.
- Phase 2 population: 263 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes.
- Reported range: mean body-weight change from -9.5% to -20.1% across Eloralintide arms versus -0.4% with placebo.
- Indirect meta-analysis (2026): a network meta-analysis reported an approximately -18% body-weight reduction for high-dose eloralintide. This is an indirect, preliminary, low-certainty estimate pooled across different studies; it is not a head-to-head trial and does not establish a ranking against other compounds.
- Interpretation: the data are not a head-to-head study versus cagrilintide, petrelintide, amycretin, semaglutide, tirzepatide or retatrutide.
Safety / side effects
Safety and tolerability
The most common adverse events reported in the Phase 2 release were mild-to-moderate gastrointestinal symptoms and fatigue, more frequent in higher arms. The release also notes lower frequency of these events with slower escalation. Long-term Phase 3 safety conclusions are not yet available.
- Most common events: gastrointestinal symptoms and fatigue, mostly mild to moderate in the available material.
- Tolerability: event frequency appears higher in higher studied arms.
- Long-term boundary: completed Phase 3 outcomes and real-world data are not available.
Reported adverse events
| Category | Reported pattern | Source context | Evidence confidence |
|---|---|---|---|
| Gastrointestinal symptoms | Mild to moderate; more frequent in higher arms. | Lilly Phase 2 release | Moderate for short-term Phase 2 context |
| Fatigue | Reported as a common adverse event. | Lilly Phase 2 release | Moderate |
| Nausea / vomiting | Related to gastrointestinal tolerability in Phase 1/2 context. | Phase 1/2 sources | Moderate |
| Dose-related tolerability | Adverse-event frequency increased in higher arms and was lower with slower escalation. | Lilly Phase 2 release | Moderate |
| Long-term safety | Completed Phase 3 outcomes are not available in the current material. | Evidence limitation | Insufficient for final conclusions |
Important Limitations & Uncertainties
- Eloralintide remains investigational and is not FDA or EMA approved.
- Completed Phase 3 outcomes are not available in the current material.
- Much of the recent Phase 2 information comes from a sponsor-reported release.
- The Phase 2 sample is smaller than large Phase 3 programs.
- Long-term real-world data are not available.
- Cross-trial comparisons with other molecules have major limitations.
Important notes
- Eloralintide remains investigational and should not be presented as an approved therapy.
- Numerical arms on this page are clinical-study arms, not use instructions.
- Phase 2 endpoints were reported without multiplicity adjustment according to Lilly’s release.
- Comparisons with other molecules are mechanistic or cross-trial and have major limitations.
Competitive landscape
These are cross-trial comparisons and do not represent head-to-head evaluation.
Cagrilintide
Amylin analog
Related amylin field, but a different molecule and development program.
Petrelintide
Amylin-based research
Useful for mechanistic comparison, not for direct efficacy ranking.
Amycretin
Amylin / GLP-1 research context
Different pharmacological strategy with dual targeting.
Retatrutide
GLP-1 / GIP / glucagon
Triple incretin/glucagon agonist, mechanistically distinct from amylin.
Semaglutide
GLP-1
Approved GLP-1 category, not amylin receptor agonism.
Tirzepatide
GIP / GLP-1
Dual incretin agonist with a different target profile than Eloralintide.
Patent / IP notes
Patent family AU2022228541B2 / WO2022187305 describes long-acting amylin receptor agonists and uses thereof and lists Eli Lilly and Co as assignee. This is patent/IP background and not clinical proof of safety or efficacy.
Bibliography
FAQ
FAQ
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →